condition Transplant – Bone Marrow

Overview

Transplant is the procedure in which a new organ or cells are placed in the body to cure a disease. In a bone marrow transplant, cells are collected from a patient or from someone else and later infused into the patient. Medication to increase the number of these cells is needed before they can be collected. After a bone marrow transplant, the person who received the cells usually has to take medications to prevent certain infections.

Drug Therapies

  • Cresemba

    Cresemba (isavuconazonium sulfate)

    Cresemba (isavuconazonium sulfate) is an azole antifungal medication given orally or intravenously to treat invasive aspergillosis or invasive mucormycosis.
    Manufacturer:
    Astellas
    Route of Administration: 
    Oral, Intravenous
    Site of Care:
    Outpatient
    Website: 
    • https://www.cresemba.com/
    phone: 
    1-800-477-6472
    Enrollment Forms:
    Synergen Prescription Form
    Patient Support Form

    Approved Indication:

    treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh at least 16 kilograms

    Conditions:

    • Invasive Aspergillosis
    • Mucormycosis
      less details
    • Fulphila

      Fulphila (pegfilgrastim-jmdb)

      Fulphila (pegfilgrastim-jmdb) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fulphila is a leukocyte growth factor that stimulates blood cell production.
      Manufacturer:
      Biocon Biologics
      Route of Administration: 
      Subcutaneous
      Site of Care:
      Outpatient
      Website: 
      • https://fulphila.com/
      phone: 
      1-833-695-2623
      Enrollment Forms:
      Synergen Prescription Form
      Patient Support Form

      Approved Indication:

      to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia

      Conditions:

      • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

        Therapeutic Area:

        • Oncology
        less details
      • Fylnetra

        Fylnetra (pegfilgrastim-pbbk)

        Fylnetra (pegfilgrastim-pbbk) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.
        Manufacturer:
        Amneal Pharmaceuticals
        Route of Administration: 
        Subcutaneous
        Site of Care:
        Outpatient
        Website: 
        • https://fylnetra.us/
        phone: 
        866-4AMNEAL (866-426-6325)
        Enrollment Forms:
        Synergen Prescription Form
        Patient Support Form

        Approved Indication:

        • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
        • to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

        Conditions:

        • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
        • Hematopoietic Syndrome of Acute Radiation Syndrome

          Therapeutic Area:

          • Oncology
          less details
        • Gengraf

          Gengraf (cyclosporine, modified)

          Gengraf (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
          Manufacturer:
          Misc.
          Route of Administration: 
          Oral
          Site of Care:
          Outpatient
          Website: 
            Enrollment Forms:
            Synergen Prescription Form

            Approved Indication:

            • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
            • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
            • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

            Conditions:

            • Solid Organ Transplant
            • Rheumatoid Arthritis
            • Plaque Psoriasis

              Therapeutic Area:

              • Cardiology
              • Dermatology
              • Hepatology
              • Nephrology
              • Rheumatology
              • Transplant
              less details
            • Granix

              Granix (tbo-filgrastim)

              Granix (tbo-filgrastim) is a colony-stimulating factor that increases circulating levels of neutrophils, a type of white blood cell.
              Manufacturer:
              Teva
              Route of Administration: 
              Subcutaneous
              Site of Care:
              Outpatient
              Website: 
              • https://www.granixhcp.com/
              Enrollment Forms:
              Synergen Prescription Form
              Patient Support Form

              Approved Indication:

              for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia in adult and pediatric patients 1 month and older

              Conditions:

              • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

                Therapeutic Area:

                • Oncology
                less details
              • Livtencity

                Livtencity (maribavir)

                Livtencity (maribavir) is an antiviral medication approved by the FDA to treat infection with cytomegalovirus (CMV) in patients who have received a transplant and have failed or are resistant to other antivirals.
                Manufacturer:
                Takeda
                Route of Administration: 
                Oral
                Site of Care:
                Outpatient
                Website: 
                • https://www.livtencity.com/
                phone: 
                1-855-268-1825
                Enrollment Forms:
                Synergen Prescription Form
                Patient Support Form

                Approved Indication:

                treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet

                Conditions:

                • Post-Transplant Cytomegalovirus (CMV) Infection

                  Therapeutic Area:

                  • Infectious disease
                  less details
                • Neoral

                  Neoral (cyclosporine, modified)

                  Neoral (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                  Manufacturer:
                  misc.
                  Route of Administration: 
                  Oral
                  Site of Care:
                  Outpatient
                  Website: 
                    Enrollment Forms:
                    Synergen Prescription Form

                    Approved Indication:

                    • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
                    • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
                    • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

                    Conditions:

                    • Solid Organ Transplant
                    • Rheumatoid Arthritis
                    • Plaque Psoriasis

                      Therapeutic Area:

                      • Cardiology
                      • Dermatology
                      • Hepatology
                      • Nephrology
                      • Rheumatology
                      • Transplant
                      less details
                    • Nivestym

                      Nivestym (filgrastim-aafi)

                      Nivestym (filgrastim-aafi) is an FDA-approved biosimilar to Neupogen. Like Neupogen, Nivestym is a leukocyte growth factor that stimulates blood cell production and can be used to prepare a patient for a bone marrow transplant.
                      Manufacturer:
                      Pfizer
                      Route of Administration: 
                      Subcutaneous
                      Site of Care:
                      Outpatient
                      Website: 
                      • https://www.pfizer.com/products/product-detail/nivestym
                      phone: 
                      1-877-744-5675
                      Enrollment Forms:
                      Synergen Prescription Form
                      Patient Support Form

                      Approved Indication:

                        • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
                        • to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
                        • to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
                        • to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
                        • to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

                      Conditions:

                      • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
                      • Hematopoietic Stem Cell Transplantation
                      • Cyclic/Congenital/Idiopathic Neutropenia

                        Therapeutic Area:

                        • Oncology
                        less details
                      • Nyvepria

                        Nyvepria (pegfilgrastim-apgf)

                        Nyvepria (pegfilgrastim-apgf) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.
                        Manufacturer:
                        Pfizer
                        Route of Administration: 
                        Subcutaneous
                        Site of Care:
                        Outpatient
                        Website: 
                        • https://www.pfizer.com/products/product-detail/nyvepriatm
                        phone: 
                        1-877-744-5675
                        Enrollment Forms:
                        Synergen Prescription Form
                        Patient Support Form

                        Approved Indication:

                        to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

                        Conditions:

                        • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

                          Therapeutic Area:

                          • Oncology
                          less details
                        • Posaconazole

                          posaconazole

                          Posaconazole is an azole antifungal medication given orally to treat Candida infections of the mouth or throat or orally or intravenously to prevent Aspergillus or Candida infections in patients with compromised immune systems.
                          Manufacturer:
                          Misc
                          Route of Administration: 
                          Oral
                          Site of Care:
                          Outpatient
                          Website: 
                            Enrollment Forms:
                            Synergen Prescription Form

                            Approved Indication:

                            • prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy
                            • treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole

                            Conditions:

                            • Aspergillosis
                            • Candidiasis
                              less details
                            • Prevymis

                              Prevymis (letermovir)

                              Prevymis (letermovir) is an antiviral medication given intravenously or by mouth to prevent infection with cytomegalovirus (CMV) in patients who have received a transplant.
                              Manufacturer:
                              Merck
                              Route of Administration: 
                              Oral
                              Site of Care:
                              Outpatient
                              Website: 
                              • https://www.prevymis.com/
                              phone: 
                              855-404-5278
                              Enrollment Forms:
                              Synergen Prescription Form
                              Patient Support Form

                              Approved Indication:

                              • prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogenic hematopoietic stem cell transplant
                              • prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])

                              Conditions:

                              • Post-Transplant Cytomegalovirus (CMV) Prophylaxis

                                Therapeutic Area:

                                • Infectious disease
                                less details
                              • Prograf

                                Prograf (tacrolimus)

                                Prograf (tacrolimus) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                                Manufacturer:
                                Astellas
                                Route of Administration: 
                                Oral
                                Site of Care:
                                Outpatient
                                Website: 
                                • https://www.prograf.com/
                                Enrollment Forms:
                                Synergen Prescription Form

                                Approved Indication:

                                prophylaxis of organ rejection in adult and pediatric patients receiving allogenic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants

                                Conditions:

                                • Solid Organ Transplant

                                  Therapeutic Area:

                                  • Cardiology
                                  • Hepatology
                                  • Nephrology
                                  • Pulmonology
                                  • Transplant
                                  less details
                                • Releuko

                                  Releuko (filgrastim-ayow)

                                  Releuko (filgrastim-ayow) is an FDA-approved biosimilar to Neupogen. Like Neupogen, Releuko is a leukocyte growth factor that stimulates blood cell production, but Releuko is not approved for stem cell mobilization prior to a bone marrow transplant.
                                  Manufacturer:
                                  Amneal Pharmaceuticals
                                  Route of Administration: 
                                  Subcutaneous
                                  Site of Care:
                                  Outpatient
                                  Website: 
                                  • https://releuko.us/
                                  phone: 
                                  866-4AMNEAL (866-426-6325)
                                  Enrollment Forms:
                                  Synergen Prescription Form
                                  Patient Support Form

                                  Approved Indication:

                                  • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
                                  • to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
                                  • to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
                                  • to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
                                  • to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
                                  • to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

                                  Conditions:

                                  • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
                                  • Hematopoietic Stem Cell Transplantation
                                  • Cyclic/Congenital/Idiopathic Neutropenia
                                  • Hematopoietic Syndrome of Acute Radiation Syndrome

                                    Therapeutic Area:

                                    • Oncology
                                    less details
                                  • Sandimmune

                                    Sandimmune (cyclosporine, unmodified)

                                    Sandimmune (cyclosporine, UNmodified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                                    Manufacturer:
                                    Misc.
                                    Route of Administration: 
                                    Oral, Intravenous
                                    Site of Care:
                                    Outpatient, Inpatient
                                    Website: 
                                      Enrollment Forms:
                                      Synergen Prescription Form

                                      Approved Indication:

                                      prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants in combination with adrenal corticosteroids

                                      Conditions:

                                      • Solid Organ Transplant

                                        Therapeutic Area:

                                        • Cardiology
                                        • Hepatology
                                        • Nephrology
                                        • Transplant
                                        less details
                                      • Udenyca

                                        Udenyca (pegfilgrastim-cbqv)

                                        Udenyca (pegfilgrastim-cbqv) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.
                                        Manufacturer:
                                        Coherus BioSciences
                                        Route of Administration: 
                                        Subcutaneous
                                        Site of Care:
                                        Outpatient
                                        Website: 
                                        • https://www.udenyca.com/hcp
                                        phone: 
                                        1-844-483-3692
                                        Enrollment Forms:
                                        Synergen Prescription Form
                                        Patient Support Form

                                        Approved Indication:

                                        • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
                                        • to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

                                        Conditions:

                                        • Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
                                        • Hematopoietic Syndrome of Acute Radiation Syndrome

                                          Therapeutic Area:

                                          • Oncology
                                          less details
                                        • Valacyclovir

                                          valacyclovir

                                          Valacyclovir is an antiviral medication used to treat or prevent infections by various strains of the herpes virus.
                                          Manufacturer:
                                          Misc
                                          Route of Administration: 
                                          Oral
                                          Site of Care:
                                          Outpatient
                                          Website: 
                                            Enrollment Forms:
                                            Synergen Prescription Form

                                            Approved Indication:

                                            • cold sores (Herpes labialis) in adult and pediatric patients
                                            • treatment of initial or recurrent genital herpes in immunocompetent adult patients
                                            • suppression of genital herpes in immunocompent or HIV-infected adult patients
                                            • reduction of transmission of genital herpes in adult patients
                                            • Herpes zoster in adult patients
                                            • chickenpox in pediatric patients

                                            Conditions:

                                            • Herpes Labialis Infection
                                            • Herpes Zoster Infection
                                            • Genital Herpes
                                            • Cold Sores
                                            • Chickenpox

                                              Therapeutic Area:

                                              • Infectious Disease
                                              less details
                                            • Valganciclovir

                                              valganciclovir

                                              Valganciclovir is an antiviral medication that targets cytomegalovirus (CMV) and is used to treat and/or prevent CMV infection in patients who have received a transplant.
                                              Manufacturer:
                                              Misc
                                              Route of Administration: 
                                              Oral
                                              Site of Care:
                                              Outpatient
                                              Website: 
                                                Enrollment Forms:
                                                Synergen Prescription Form

                                                Approved Indication:

                                                • treatment of cytomegalovirus retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)
                                                • prevention of cytomegalovirus disease in adult kidney, heart, or kidney-pancrease transplant patients at high risk
                                                • prevention of cytomegalovirus disease in pediatric kidney or heart transplant patients at high risk

                                                Conditions:

                                                • Cytomegalovirus

                                                  Therapeutic Area:

                                                  • Infectious Disease
                                                  less details
                                                • Voriconazole

                                                  voriconazole

                                                  Voriconazole is a triazole antifungal agent given intravenously or by mouth to treat invasive fungal infections caused by Aspergillus sp, Candida sp, Fusarium sp, and others. In immunocompromised patients, voriconazole is also used to prevent these infections.
                                                  Manufacturer:
                                                  Misc
                                                  Route of Administration: 
                                                  Oral, Intravenous
                                                  Site of Care:
                                                  Outpatient
                                                  Website: 
                                                    Enrollment Forms:
                                                    Synergen Prescription Form

                                                    Approved Indication:

                                                    • treatment of invasive aspergillosis
                                                    • treatment of Candidemia in nonneutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds
                                                    • treatment of esophageal candidiasis
                                                    • treatment of serious fungal infections caused by Scedosporium apiospermum and Fusium spp. in patients intolerant of or refractory to other therapy

                                                    Conditions:

                                                    • Aspergillosis
                                                    • Candidiasis

                                                      Therapeutic Area:

                                                      • Infectious Disease
                                                      less details

                                                    Resources

                                                    Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.

                                                    Dana-Farber Cancer Institute
                                                    Leukemia Research Foundation
                                                    National Bone Marrow Transplant Link

                                                    Stay Connected

                                                    Get the latest news and updates

                                                    Contact Us Now